Claude Franceschi: Comparing the Efficacy of CHIVA and Conventional Stripping and Ablation Techniques
Claude Franceschi, Angiologist Consultant Teacher at Center Marie‑Thérèse, shared a post on LinkedIn about a recent article by Jinghe Zhu et al, published in Annals of Vascular Surgery:
“Preserving the great saphenous vein (GSV), which is the first-choice conduit for potential future arterial grafting, is possible with CHIVA.
Systematic review and meta-analysis comparing the efficacy of CHIVA and conventional stripping and ablation techniques
Objective: Chronic venous disease (CVD), particularly primary lower extremity varicose veins, is a prevalent global health issue. The CHIVA technique is a hemodynamic-based, vein-preserving strategy proposed as a minimally invasive alternative to traditional treatments such as high ligation and stripping (HLS) or endovenous thermal ablation (e.g., radiofrequency or laser).
The CHIVA technique is designed to treat varicose veins while preserving the great saphenous vein (GSV), which is the first-choice conduit for potential future arterial grafting, especially at the infra-inguinal level. It offers theoretical advantages of reduced trauma, fewer complications, and lower recurrence potential. This systematic review aims to evaluate the efficacy and safety of CHIVA relative to established techniques based on current evidence.”
Title: Systematic Review and Meta-Analysis Comparing the Efficacy of CHIVA and Conventional Stripping and Ablation Techniques
Authors: Jinghe Zhu, Hongjie Cui, Menglong Li, Yingfeng Wu
Read the Full Article on Annals of Vascular Surgery․
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 3, 2026, 08:53Jamie’s Journey Through a Decade with Immune Thrombocytopenia – ITP Support Association
-
Sep 3, 2026, 08:00Beth Meneley: When Transfusion Is Not an Option – HBOT for Exceptional Blood Loss Anemia
-
Sep 3, 2026, 06:27Seyed Mehrab Safdari: Unmasking Factor VII Padua to Prevent Unnecessary Therapy and Thrombotic Risk
-
Sep 3, 2026, 04:09Pedro Perez: Are We Entering a New Era in the Treatment of Intermediate-High-Risk PE?
-
Sep 3, 2026, 04:01Marianne Yee: Supporting Families and Transformative Therapies in Sickle Cell Disease
-
Sep 3, 2026, 03:51Strengthening Bleeding Disorders Care in New Zealand – WFH
-
Sep 3, 2026, 03:42Nathan Connell: FDA Approves Rusfertide for Polycythemia Vera
-
Sep 3, 2026, 03:28Katrina Snow: Learning More About Sickle Cell Disease This September
-
Sep 3, 2026, 01:19Himanshu Aggarwal: 1 mg/kg/d Thalidomide Non-Inferior to Standard Dose in Transfusion-Dependent Thalassemia